Hipocalcemia severa posdenosumab

Nefrologia

Volumn 33, Issue 4, 2013, Pages 614-615

  Martín Baez, Isabel M ^a   Blanco García, Raquel ^a   Alonso Suárez, Mario ^a   Cossio Aranibar, Cynthia ^a   Beato Coo, Laura V ^a   Fernández Fleming, Francisco ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; MONOCLONAL ANTIBODY;

CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; HYPOCALCEMIA; LETTER; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; HYPOCALCEMIA; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84883037797     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2013.Apr.11922     Document Type: Letter

References (6)

1. Prolia (denosumab) product monograph. Mississauga. ON: Amgen Canada Inc; 2011.
2. Perazella MA, Markowitz GS. Biphosphonate nephrotoxicity. Kidney Int 2008;74:1385-93.
3. Cummings SR, San Martín J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65.
4. Padagas J, Colloton M, Shalhoub V, Kostenuik P, Morony S, Munyakazi L, et al. The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism. Calcif Tissue Int 2006;78:35-44.
5. Westenfeld R, Ketteler M, Brandenburg VM.Anti-RANKL therapy-implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with various low bone mineral density. Nephrol Dial Transplant 2006;21(8):2075-7.
6. Block GA, Bone HG, Fang L, Lee E, Padhi D. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012;27:1471-9.